Cervical
-
(101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic,
Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients
with Advanced Solid Tumors
-
(167-19) Phase 2 Study of Anti-PD-1 Independently or in Combination With
Anti-CTLA-4 in Second-Line Cervical Cancer (Phase 2 clinical trial, appropriate for patients with cervical cancer.)
-
(178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity
of ASTX029 in Subjects With Advanced Solid Tumors
-
(187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal
Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1
Monoclonal Antibody, in Subjects with Advanced Cancer (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)
-
(188-18) A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)
-
(189-18) ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With
Metastatic Solid Tumors (Phase 2 clinical trial, appropriate for patients with metastatic solid tumors.)
-
(205-19) Study to Assess AFM24 in Advanced Solid Cancers (Phase 1/2a clinical trial, appropriate for patients with advanced solid tumors.)
-
(221-19) Study of GNX102 in Patients With Advanced Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)
Certain clinical trials may not be listed on ClinicalTrials.gov. To learn
more about these or other clinical trials, please call 949-764-5543 or
contact us online.